Adaptive is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company offers testing instruments for diagnose, treat, and monitor disease. The company serves customers in the United States.

AngioDynamics designs, manufactures and sells medical, surgical and diagnostic devices for the treatment of peripheral vascular disease, vascular access and for use in oncology and surgical settings. The company's business units are: Oncology/Surgery, which provides a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the NanoKnife System; Vascular Interventions and Therapies, which supports the medical areas of venous insufficiency, thrombus management, and peripheral products; and Vascular Access, which includes peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters and related accessories and supplies.

Bio-Rad Laboratories is a manufacturer and distributor of its own life science research and clinical diagnostics products. The company has two primary segments: Life Science, which is engaged in the life sciences market and develops, manufactures and markets reagents, apparatus and laboratory instruments; and Clinical Diagnostics, which designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the diagnostics market. The company sells its products and services to a client base comprised of scientific research, healthcare, education and government customers.

Bruker is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. Majority of the company's products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The company also develops, manufactures and distributes a range of field analytical systems for chemical, biological, radiological, nuclear and explosives detection. The company also develops, manufactures and markets high and low temperature superconducting materials and devices based primarily on metallic low temperature superconductors. The company's segments include: Bruker Scientific Instruments and Bruker Energy and Supercon Technologies.

Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make treatment decisions. The company's main product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. The company also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. The company is developing additional products in treating their patients' skin cancer, such as DecisionDx-SCC.

Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. This enables physicians to select therapeutic that matches and inhibits a patient's cellular dysfunction.

Charles River Laboratories International is a contract research organization. The company has a laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. The company's segments are: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides DSA services, including in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development; and Manufacturing Support, which ensures the production and release of products manufactured by the company's clients.

Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. The company's target indications include diseases, such as Alzheimer's disease and Parkinson's disease, as well as orphan indications, such as mucopolysaccharidosis type II, and amyotrophic lateral sclerosis. The company's Transport Vehicle technology enables several classes of biotherapeutics to cross the blood-brain barrier (BBB), including enzymes, antibodies, proteins and oligonucleotides. This technology is designed to engage BBB transport receptors, which are expressed in brain capillaries and facilitate transport of proteins into the brain.

Exelixis is an oncology-focused biotechnology company that involved in the discovery, development and commercialization of new medicines for cancers. The company's marketd products are: CABOMETYX? (cabozantinib) tablets for renal cell carcinoma and previously treated hepatocellular carcinoma; and COMETRIQ? (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. The company's products resulting from its discovery efforts are: COTELLIC? (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat melanoma; and MINNEBRO? (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

Fulgent Genetics is a holding company. Through its subsidiaries, the company is a technology company providing genetic testing and providing physicians with diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to provide test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels to meet customer needs. The company's test menu includes single-gene tests and panels that test for genetic conditions, including various cancers, cardiovascular diseases, neurological disorders and pediatric conditions.

Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. The company's approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE? Drug Delivery Technology (ENHANZE). The company licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.

IDEXX Laboratories develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company operates primarily through three business segments: Companion Animal Group, which provides diagnostic and information management-based products and services for the veterinary market; Water Quality Products, which designs, develops, manufactures, and distributes products used in the detection of various microbiological parameters in water; and Livestock, Poultry and Dairy, which provides diagnostic products and services for livestock and poultry health.

Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. The company provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using the company's services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). The company provides NIPT services through its partner laboratories that direct samples to the company on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. The company also provides support services to customers who have purchased its products.

Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. The company has two commercial medicines, SPINRAZA and TEGSEDI. SPINRAZA (nusinersen) injection for intrathecal use is a survival motor neuron-2, directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI (inotersen) injection is a Generation 2+ antisense medicine and an approved subcutaneous RNA-targeting medicine designed to treat people with polyneuropathy caused by hereditary transthyretin amyloidosis.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company's main product candidate, MGL-3196 (resmetirom), is a proprietary, orally administered, small molecule, liver-directed, thyroid hormone receptor-? selective agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states including non-alcoholic steatohepatitis.

Pacific Biosciences of California designs, develops and manufactures sequencing systems. Based on its Single Molecule, Real-Time sequencing technology, the company's products enable: de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in gene families, and find genes; targeted sequencing to characterize genetic variations; and real-time kinetic information for epigenome characterization. The PacBio RS II, Sequel, and Sequel II Systems conduct, monitor, and analyze biochemical sequencing reactions.

PerkinElmer is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The company operates in the following segments: Discovery and Analytical Solutions and Diagnostics. The company's Discovery and Analytical Solutions segment serves the life sciences and applied markets. The life sciences market consists of the life sciences research market and laboratory services market whereas the applied markets consist of environmental, food and industrial markets. In its Diagnostics segments, the company provides instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research personnel to help improve the health of families.

Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. The company's bioprocessing business is comprised of: Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and OEM products, which are represented by its Protein A affinity ligands and cell culture growth factor products

Thermo Fisher Scientific is engaged in serving science. The company's segments include: Life Sciences Solutions, which provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, which provides instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field; and Specialty Diagnostics, which provides diagnostic test kits, reagents, culture media, instruments and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.

Veracyte is a genomic diagnostics company. The company's products include the following: Afirma Genomic Sequencing Classifier and Xpression Atlas, which includes the Afirma GSC and Xpression Atlas; Percepta Bronchial Genomic Classifier, which improves lung cancer diagnosis by improving the performance of diagnostic bronchoscopies; Envisia Genomic Classifier, which improves diagnosis of idiopathic pulmonary fibrosis; and Prosigna Breast Cancer Prognostic Gene Signature Assay, which uses genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease.

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company develops and commercializes therapeutics and medicines for the treatments and preventions for viral and bacterial diseases. The company serves customers in the State of California.

Waters is a holding company. Through its subsidiaries, the company is a specialty measurement company. The company primarily designs, manufactures, sells and services high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. In addition, the company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA? product line. The company is also a developer and supplier of software-based products that interface with its instruments, as well as other manufacturers' instruments.